PepGen Inc.
NASDAQ:PEPGBiotechnology
+$0.09 today
- Market cap
- $265.27M
- Beta
- 1.93
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.12
Volume 3.39M
Average 1.37M
PEPG Total Current Liabilities
All obligations due within one year.
PepGen Inc.NASDAQ: PEPG
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 56.1% from a year ago
Total current liabilities stood at $8.96M at the end of Q1 FY2026, down 56.1% from a year earlier and down 29.1% from the prior quarter. Over 3 fiscal years it compounded at -12.4% a year.
Context
- Total current liabilities amounted to 5.7% of total assets at the end of Q1 FY2026, down 10.3 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -56.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 12.65M USD
- Year-over-year change
- -24.3%
- 4-year CAGR
- +5.2%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.65M | -24.3% |
| FY2024 | 2024-12-31 | 16.7M | -4.8% |
| FY2023 | 2023-12-31 | 17.53M | -6.9% |
| FY2022 | 2022-12-31 | 18.83M | +82.4% |
| FY2021 | 2021-12-31 | 10.32M | — |
Total Current Liabilities vs competitors
How PEPG compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -56.1% is the 7th highest of 8, against a peer median of -2.1%.
- Total current liabilities amounts to 5.7% of total assets for PEPG, versus a peer median of 12.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $40.97M USD | -62.7% | -9.5% | 17.1% | |
| Mar 2026 | $30.69M USD | +9.0% | -31.9% | 10.8% | |
| Mar 2026 | $18.21M USD | -2.9% | +0.3% | 4.9% | |
| Mar 2026 | $18.14M USD | +56.1% | +17.9% | 12.6% | |
| Mar 2026 | $14.46M USD | +8.8% | +28.1% | 29.4% | |
| Mar 2026 | $8.96M USD | -56.1% | -12.4% | 5.7% | |
| Mar 2026 | CHF 8.77M CHF | -2.1% | -13.9% | 10.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $7.23M USD | -36.7% | +5.7% | 31.9% |
| Peer median (excluding PEPG) | — | -2.1% | +0.3% | 12.6% | |
Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 132.9M | 181.75M | 80.77M | 49.42M | 60.51M |
| Short-term Investments | 0 | 0 | 29.63M | 70.77M | 87.94M |
| Net Receivables | 4.74M | 58K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.27M | 2.27M | 3.57M | 2.51M |
| Total Current Assets | 139.99M | 186.08M | 112.68M | 123.76M | 150.96M |
| Property, Plant & Equipment (Net) | 636K | 29.88M | 28.38M | 25.15M | 21.02M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.47M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.55M | 1.47M | 1.99M | 1.97M | 1.92M |
| Total Non-current Assets | 3.66M | 31.36M | 30.37M | 27.12M | 22.94M |
| Total Assets | 143.64M | 217.44M | 143.05M | 150.88M | 173.91M |
| Account Payables | 3.24M | 1.36M | 1.01M | 1.75M | 822K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 2.57M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.21M | 2.44M | 2.37M | 3.62M | 4.66M |
| Total Current Liabilities | 10.32M | 18.83M | 17.53M | 16.7M | 12.65M |
| Long-term Debt | 0 | 0 | 0 | 0 | 13.82M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 226K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 226K | 18.98M | 17.1M | 15.57M | 13.82M |
| Total Liabilities | 10.55M | 37.81M | 34.63M | 32.26M | 26.46M |
| Common Stock | 0 | 2K | 2K | 3K | 7K |
| Retained Earnings | (33.75M) | (102.86M) | (181.48M) | (271.46M) | (361.12M) |
| Accumulated OCI | 17K | (81K) | 34K | 23K | 11K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 133.09M | 179.63M | 108.42M | 118.62M | 147.44M |
| Total Debt | 0 | 24.53M | 20.1M | 18.66M | 17M |
| Net Debt | (132.9M) | (157.22M) | (60.67M) | (30.76M) | (43.51M) |
PepGen Inc.
NASDAQ:PEPG
Intrinsic Alpha fair value
Locked
Current Price
$3.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.